Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS)

• DOI: 10.1164/rccm.202312-2311oc
• Publication Date: 2024-08-30T15:40:50Z
• Authors: Dave Singh; Fernando J. Martinez; John R. Hurst; MeiLan K. Han; Chris P. Gale; Martin Fredriksson; Dobrawa Kisielewicz; Alec Mushunje; Charlotta Movitz; Nikki Ojili; Himanshu Parikh; Niki Arya; Karin Bowen; Mehul Patel
• Keywords: Post-hoc analysis; Post hoc

Chronic obstructive pulmonary disease (COPD) is associated with increased risk of cardiovascular and cardiopulmonary events. In the Phase III, 52-week ETHOS trial (NCT02465567), triple therapy budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates moderate/severe exacerbations all-cause mortality versus dual glycopyrrolate/formoterol (GFF) or budesonide/formoterol (BFF). However, effect BGF on events GFF remains unevaluated. Further, time to first severe exacerbation has not been reported.